Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1).
| CAS No. | 1834610-13-7 |
| Chemical Name | Lumasiran |
| Synonyms | ALN-G01 |
| SMILES | Not available |
| Formula | Not available |
| M.Wt | 16339.00 |
| Purity | >95% |
| Storage | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Shipping condition | Ships from Shanghai; packaging confirmed at order. |
| Publication | Not available |
| Product classification | siRNA/ASOs/Aptamer drugs |
The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.
Solvent volumes update from the molecular weight above.
| Mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 0.6120 mL | 0.1224 mL | 0.0612 mL |
| 25 mg | 1.5301 mL | 0.3060 mL | 0.1530 mL |
| 50 mg | 3.0602 mL | 0.6120 mL | 0.3060 mL |
| 100 mg | 6.1203 mL | 1.2241 mL | 0.6120 mL |
| 250 mg | 15.3008 mL | 3.0602 mL | 1.5301 mL |
Contact our team with the catalog number and requested quantity.